Research Guide
Retatrutide: A Research Guide
Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors, and has produced the highest body weight reductions documented for any single metabolic compound to date. Phase 2 data shows the highest-dose cohort had not reached a weight loss plateau by the end of the 48-week study period.
Sources
Jastreboff et al., NEJM 2023. For research use only. Not approved by the FDA. Not medical advice.
Mechanism
The addition of glucagon receptor agonism, absent from dual-agonist compounds, accelerates hepatic fat oxidation through a pathway independent of GLP-1 and GIP activity, giving retatrutide three simultaneous fat-reduction mechanisms. MRI data shows liver fat content dropping by more than 80% in many study participants, often faster than overall body weight change.
Reconstitution & Storage
Supplied as a lyophilized powder, this compound should be reconstituted with bacteriostatic water before use. Use the reconstitution calculator on our FAQ page to determine concentration and draw volume for your vial size and target dose.
Open the reconstitution & dosing calculator →
Referenced Research Protocols
Phase 2 dose-escalation protocols in the cited literature ran across multiple cohorts over a 48-week period. This guide summarizes published research design, not usage instructions.